برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Sevenfact (coagulation factor VIIa (recombinant)-jncw) Injection Date of Approval: April 1, 2020 Company: HEMA Biologics, LLC Treatment for: Hemophilia A or B with Inhibitors Sevenfact (coagulation factor VIIa [recombinant]-jncw) is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). https://t.me/ppdprogram

➡️Zeposia (ozanimod) Capsules Date of Approval: March 25, 2020 Company: Bristol-Myers Squibb Company Treatment for: Multiple Sclerosis, Ulcerative Colitis Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults; and moderately to severely active ulcerative colitis (UC) in adults. https://t.me/ppdprogram

➡️Durysta (bimatoprost) Implant Date of Approval: March 3, 2020 Company: Allergan plc Treatment for: Glaucoma, Open Angle, Intraocular Hypertension Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). https://t.me/ppdprogram

➡️Advil Dual Action (ibuprofen and acetaminophen) Tablets Date of Approval: February 28, 2020 Company: GSK Consumer Healthcare Treatment for: Pain Advil Dual Action (ibuprofen with acetaminophen) is an over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug (NSAID) contained in Advil) and acetaminophen (the active ingredient in Tylenol) for the relief of pain. https://t.me/ppdprogram

➡️Nurtec ODT (rimegepant) Orally Disintegrating Tablets (ODT) Date of Approval: February 27, 2020 Company: Biohaven Pharmaceutical Holding Company Ltd. Treatment for: <a href="https://www.drugs.com/condition/migraine.html">Migraine</a>; <a href="https://www.drugs.com/condition/migraine-prophylaxis.html">Migraine Prophylaxis</a> Nurtec ODT (rimegepant) is an orally-dosed calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine with or without aura, and the preventive treatment of episodic migraine, in adults. https://t.me/ppdprogram

➡️Barhemsys (amisulpride) Injection Date of Approval: February 26, 2020 Company: Acacia Pharma Treatment for: Nausea/Vomiting, Postoperative Barhemsys (amisulpride) is a dopamine-2 (D2) antagonist for the management of post-operative nausea and vomiting (PONV). https://t.me/ppdprogram

➡️Nexletol (bempedoic acid) Tablets Date of Approval: February 21, 2020 Company: Esperion Therapeutics, Inc. Treatment for: High Cholesterol, Familial Heterozygous Nexletol (bempedoic acid) is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-Cholesterol. https://t.me/ppdprogram

➡️Pizensy (lactitol) Powder for Oral Solution Date of Approval: February 12, 2020 Company: Braintree Laboratories, Inc. Treatment for: Chronic Idiopathic Constipation Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults. https://t.me/ppdprogram

➡️Gloperba (colchicine) Oral Solution Date of Approval: January 30, 2019 Company: Romeg Therapeutics, LLC Treatment for: Gout Gloperba (colchicine) is an oral solution formulation of the approved drug colchicine indicated for prophylaxis of gout flares in adults. https://t.me/ppdprogram

➡️Wixela Inhub (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: January 30, 2019 Company: Mylan N.V. Treatment for: Asthma, COPD Wixela Inhub (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub is the first approved generic version of Advair Diskus. https://t.me/ppdprogram

➡️Tosymra (sumatriptan) Nasal Spray Date of Approval: January 25, 2019 Company: Dr. Reddy's Laboratories, Inc. Treatment for: Migraine Tosymra (sumatriptan) is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. https://t.me/ppdprogram

➡️Ontruzant (trastuzumab-dttb) for Injection Date of Approval: January 18, 2019 Company: Samsung Bioepis Co., Ltd. Treatment for: Breast Cancer, Gastric Cancer Ontruzant (trastuzumab-dttb) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. https://t.me/ppdprogram

➡️Recorlev (levoketoconazole) Capsules Date of Approval: December 30, 2021 Company: Xeris Biopharma Holdings Treatment for: Cushing's Syndrome Recorlev (levoketoconazole) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome https://t.me/ppdprogram

➡️Leqvio (inclisiran) Injection Date of Approval: December 22, 2021 Company: Novartis Treatment for: High Cholesterol, Familial Heterozygous Leqvio (inclisiran) is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA used to reduce low-density lipoprotein cholesterol. https://t.me/ppdprogram

➡️Yusimry (adalimumab-aqvh) Injection Date of Approval: December 17, 2021 Company: Coherus BioSciences, Inc. Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis Yusimry (adalimumab-aqvh) is a tumor necrosis factor (TNF) blocker biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. https://t.me/ppdprogram

➡️Vyvgart (efgartigimod alfa-fcab) Injection Date of Approval: December 17, 2021 Company: argenx SE Treatment for: Myasthenia Gravis Vyvgart (efgartigimod alfa-fcab) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. https://t.me/ppdprogram

➡️Tezspire (tezepelumab-ekko) Injection Date of Approval: December 17, 2021 Company: Amgen and AstraZeneca Treatment for: Asthma Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. https://t.me/ppdprogram

➡️Dartisla ODT (glycopyrrolate) Orally Disintegrating Tablets Date of Approval: December 16, 2021 Company: Edenbridge Pharmaceuticals, LLC Treatment for: Peptic Ulcer Dartisla ODT (glycopyrrolate) is an anticholinergic indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. https://t.me/ppdprogram

➡️Tarpeyo (budesonide) Delayed Release Capsules - formerly Nefecon Date of Approval: December 15, 2021 Company: Calliditas Therapeutics AB Treatment for: IgA Nephropathy Tarpeyo (budesonide) is a targeted release formulation of the approved corticosteroid budesonide indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). https://t.me/ppdprogram

➡️Xaciato (clindamycin phosphate) Vaginal Gel - formerly DARE-BV1 Date of Approval: December 7, 2021 Company: Daré Bioscience, Inc. Treatment for: Bacterial Vaginosis Xaciato (clindamycin phosphate) is a topical lincosamide antibacterial for the vaginally-administered treatment of bacterial vaginosis in female patients 12 years of age and older. https://t.me/ppdprogram